mAbxience and Amneal enter into an agreement for bevacizumab biosimilar in the United StatesMiguel Martínez-Cava2018-09-24T17:54:06+02:00May 23, 2018|News|
Biosimilars reduce healthcare costs by up to 40% and increase patient accessibility to innovative treatmentsMiguel Martínez-Cava2018-05-07T15:49:40+02:00May 7, 2018|News|
5th Castilla y León’s Best Director AwardsMiguel Martínez-Cava2018-05-07T15:47:49+02:00April 30, 2018|News|